SUPPLEMENTARY MATERIAL. Journal: Clinical Drug Investigation
|
|
|
- Laurel Welch
- 6 years ago
- Views:
Transcription
1 SUPPLEMENTARY MATERIAL Journal: Clinical Drug Investigation Title: Safety profile of biologic drugs in the treatment of inflammatory bowel diseases: a systematic review and network meta-analysis of randomized controlled trials Paweł Moćko (P.M.) 1, Paweł Kawalec (P.K.) 1, Andrzej Pilc (A.P.) 1,2 1 Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Kraków, Poland 2 Department of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland Corresponding author: Paweł Kawalec MD, PhD Address: Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, ul. Grzegórzecka 20, Kraków, Poland. Phone: ; fax: ; pawel.kawalec@uj.edu.pl
2 Supplementary material Table 1. MeSH subject headings and EMTREE keywords used in constructed search strategy for the primary studies Keywords (Combined with Boolean operator(s), OR/AND) Medical condition Intervention I (UC, CD) Intervention II (UC) Intervention III (UC, CD) Intervention IV (UC, CD) Intervention V (CD) Methodological limits Language limits Ulcerative Colitis OR Colitis Ulcerosa OR Colitis Ulcerativa OR Ulcerous Colitis OR Ulcerative Colorectitis OR Colitis Ulcerosa Chronica OR Chronic Ulcerative Colitis OR Chronic Ulceration OR Idiopathic Proctocolitis OR Ulcerative Procto Colitis OR Ulcerative Proctocolitis OR Histiocytic Ulcerative Colitis OR Mucosal Colitis OR Colitis Gravis Crohn's Disease OR Crohn Disease OR Crohns Disease OR Colon Crohn Disease OR Colonic Crohn Disease OR Crohn's Enteritis OR Regional Enterocolitis OR Regional Enteritis OR Enteritis Regionalis OR Colon Regional Enteritis OR Regional Colitis OR Granulomatous Enteritis OR Ileocolitis OR Granulomatous Colitis OR Terminal Ileitis OR Regional Ileitides OR Regional Ileitis OR Morbus Crohn Infliximab OR Monoclonal Antibody ca2 OR MAb ca2 OR Remsima OR Remicade OR Avakine OR Inflectra OR Revellex Golimumab OR cnto 148 OR cnto148 OR Simponi Adalimumab OR D2E7 Antibody OR Monoclonal Antibody D2E7 OR LU OR Humira OR Trudexa Vedolizumab OR mln0002 OR mln 0002 OR mln 02 OR mln02 OR Monoclonal Antibody mln 02 OR Monoclonal Antibody ldp 02 OR ldp 02, ldp02 OR Entyvio Certolizumab OR Certolizumab Pegol OR Cimzia OR CDP870 OR CDP 870 OR Pha OR Pha OR Pegylated Tumor Necrosis Factor Alpha Antibody Fab Fragment OR Pegylated Tumour necrosis Factor Alpha Antibody Fab Fragment PubMed: humans, Randomized Controlled Trial; Embase: humans, Embase only, Randomized Controlled Trial; Cochrane: Cochrane Central Register of Controlled Trials, word variations have been searched Only English publications
3 Supplementary material Table 2. Summary of the safety profile of biologic drugs Outcome Number of events/number of participants (%) Long-term follow-up ADA ADA GLM GLM VDZ VDZ IFX IFX Biological Placebo Biological Placebo Biological Placebo Biological Placebo Any AEs 713/ / / / / / / /121 (85) (85) (73) (66) (84) (81) (88) (85) SAEs 112/ /660 35/308 12/ / /576 99/ /453 (11) (14) (11) (8) (19) (14) (22) (26) AEs leading to 81/ /660 22/308 (7) 10/156 n/d n/d 46/463 29/466 discontinuation (8) (13) (6) (10) (6) of study drug Injection site 54/496 17/399 46/308 18/156 33/814 (4) 14/301 79/463 55/466 reaction (11) (4) (15) (12) (5) (17) (12) Infections 519/ / /308 44/ / /576 53/121 47/121 (51) (44) (39) (28) (51) (48) (44) (39) Serious infections 15/542 (3) 11/286 (4) n/d n/d 45/814 (6) 9/301 (3) 12/331 (4) 17/332 (5) Infections n/d n/d 83/308 24/156 n/d n/d 150/ /453 requiring (27) (15) (33) (30) antimicrobial treatment Abdominal pain 39/517 (8) 17/261 22/308 (7) 4/ / /576 11/121 16/121 (7) (3) (8) (9) (11) (13) Middle-term follow-up IFX IFX CZP CZP Biological Placebo Biological Placebo 116/ / / /541 (72) (65) (75) (74) 16/162 28/164 46/547 (8) 37/541 (10) (17) (7) n/d n/d n/d n/d 17/ (164 15/547 (3) 78/541 (10) (7) (14) n/d n/d n/d n/d n/d n/d n/d n/d n/d n/d n/d n/d 10/121 (8) 14/123 37/331 37/329 (11) (11) (11)
4 Outcome Number of events/number of participants (%) Long-term follow-up Middle-term follow-up ADA Biological ADA Placebo GLM Biological GLM Placebo VDZ Biological VDZ Placebo IFX Biological IFX Placebo IFX Biological IFX Placebo CZP Biological CZP Placebo Arthralgia 61/517 (12) 23/261 (9) 19/308 (6) 12/156 (8) 166/1434 (12) 65/576 (11) 21/121 (17) 18/121 (15) 16/121 (13) 6/123 (5) 22/331 (7) 16/329 (5) Headache 55/517 (11) 15/261 (6) 24/308 (8) 14/156 (9) 177/1434 (12) 75/576 (13) 22/121 (18) 27/121 (22) 19/121 (16) 18/123 (15) 75/547 (14) 68/541 (13) Nausea 41/517 (8) 16/261 (6) n/d n/d 128/1434 (9) 49/576 (9) 14/121 (12) 14/121 (12) 6/121 (5) 9/123 (7) 26/331 (8) 27/329 (8) Cough n/d n/d 14/308 (5) 5/156 36/620 (6) 13/275 n/d n/d n/d n/d n/d n/d (3) (5) Nasopharyngitis 67/554 25/279 35/308 11/156 80/620 26/275 1/11 (9) 2/13 n/d n/d n/d n/d (12) (9) (11) (7) (13) (9) (15) Pyrexia 31/517 (6) 14/261 n/d n/d 103/814 40/301 n/d n/d n/d n/d n/d n/d (5) (13) (13) Pharyngitis n/d n/d 13/308 (4) 4/156 n/d n/d 12/121 10/121 n/d n/d n/d n/d (3) (10) (8) URTI 28/517 (5) 16/261 (6) 17/308 (6) 4/156 (3) 236/1434 (16) 77/576 (13) 20/121 (17) 28/121 (23) n/d n/d n/d n/d The table includes only data for the endpoints for which it was possible to conduct a network meta-analysis; ADA adalimumab; AE adverse event; CZP certolizumab pegol; GLM golimumab; IFX infliximab; n/d no data; SAE serious adverse event; URTI upper respiratory tract infection; VDZ vedolizumab
5 Supplementary material Table 3. Summary of the safety profile of biologic drugs in the extended phases Biologic drugs Infliximab Adalimumab Certolizumab pegol Extension phase of study ACT-1 and ACT-2 ULTRA CHARM Watanabe et al RECISE 1 and RECISE 2 Duration Up to 3 years Up to 4 years Up to 2 years Up to 4 years Up to 148 weeks Up to 7 years Outcome E/100-PY E (E/100-PY)* n/n=854 E (E/100- E (E/100- n/n=79 E (E/100- n/n=595 (%) (N=230) (N=1010) (%) PY)** (N=854) PY)^ (N=854) (%) PY)^^ (N=79) Any AEs (344.6) 804 (94.1) 7644 (713.0) 9736 (583.1) 7 (100.0) 1154 (743.1) 525 (88.2) SAEs (17.7) 219 (25.6) 357 (33.3) 517 (31.0) 49 (62.0) 88 (56.7) 240 (40.3) AEs leading to (10.7) 174 (20.4) 212 (19.8) 252 (15.1) 28 (35.4) 29 ( (34.3) discontinuation of study drug 7) AE leading to death (0.1) n/d n/d 2 (0.1) n/d n/d 4 (0.7) AE related to study drug 4.63 n/d 475 (55.6) 1637 (152.7) 1933 (115.8) 47 (59.5) 127 (81.8) 252 (42.4) Infection 99 n/d 510 (59.7) 1424 (132.8) 1966 (117.7) 68 (86.1) 337 (217.0) n/d Serious infection (3.4) 56 (6.6) 69 (6.4) 102 (6.1) 9 (11.4) 11 (7.1) n/d Infections requiring 41 n/d n/d n/d n/d n/d n/d n/d antimicrobial treatment Malignancy (1.0) 11 (1.3) 12 (1.1) 26 (1.6) 0 0 n/d Injection site pain n/d n/d 54 (6.3) 59 (5.5) 125 (7.5) n/d n/d n/d Injection site reaction (10.5) n/d n/d n/d 6 (7.6) 6 (3.9) n/d Opportunistic infection n/d 6 (0.3) 19 (2.2) 22 (2.1) 22 (1.3) 1 (1.3) 1 (0.6) 114 (19.2) Tuberculosis n/d 1 (<1) 3 (0.4) 3 (0.3) 3 (0.2) 0 0 n/d Congestive heart failure n/d 4 (0.2) n/d
6 Biologic drugs Infliximab Adalimumab Certolizumab pegol Extension phase of study ACT-1 and ACT-2 ULTRA CHARM Watanabe et al RECISE 1 and RECISE 2 Duration Up to 3 years Up to 4 years Up to 2 years Up to 4 years Up to 148 weeks Up to 7 years Outcome E/100-PY E (E/100-PY)* n/n=854 E (E/100- E (E/100- n/n=79 E (E/100- n/n=595 (%) (N=230) (N=1010) (%) PY)** (N=854) PY)^ (N=854) (%) PY)^^ (N=79) Demyelinating disorder 0 3 (0.1) 2 (0.2) 3 (0.3) 3 (0.2) 0 0 n/d Hepatic event n/d 12 (0.5) n/d n/d 53 (3.2) 21 (26.6) 36 (23.2) n/d Allergic reaction n/d n/d n/d n/d n/d 1 (1.3) 1 (0.6) n/d Lupus-like syndrome n/d n/d n/d n/d n/d 0 0 n/d Blood disorder n/d n/d n/d n/d n/d 2 (2.5) 2 (1.3) n/d Lymphoma n/d 3 (0.1) n/d n/d n/d n/d n/d n/d AE adverse event; E events; E/100-PY events/100 patient-years; PY patient-year.*py=2338.0; **PY=1072.1; ^PY=1669.7; ^^PY=155.3
7 Supplementary material Figure 1. Forest plot for results from pair-wise meta-analyses (blank squares) and from network meta-analysis (solid squares) for outcomes: A) any adverse events (AEs); B) serious AEs; C) AEs leading to discontinuation of study drug; D) injection site reaction; E) infections; F) serious infections; G) infections requiring antimicrobial treatment long-term follow-up. Squares represent pooled estimates of OR. Lines for 95% confidence intervals (CIs) represent 95% CIs in pair-wise meta-analyses and 95% credible intervals (CrIs) in network meta-analysis. The result of a single study was provided as OR with 95% CI.
8 Supplementary material Figure 2. Forest plot for results from pair-wise meta-analyses (blank squares) and from network meta-analysis (solid squares) for outcomes: A) abdominal pain; B) arthralgia; C) cough; D) headache; E) nausea; F) nasopharyngitis; G) pharyngitis; H) pyrexia; I) upper respiratory tract infection long-term follow-up. Squares represent pooled estimates of OR. Lines for 95% confidence intervals (CIs) represent 95% CIs in pair-wise meta-analyses and 95% credible intervals (CrIs) in network meta-analysis. The result of a single study was provided as OR with 95% CI.
9 Supplementary material Figure 3. Forest plot for results from pair-wise meta-analyses (blank squares) and from network meta-analysis (solid squares) for outcomes: A) any adverse events; B) serious adverse events; C) injection site reaction; D) abdominal pain; E) arthralgia; F) headache; G) nausea middle-term followup. Squares represent pooled estimates of OR. Lines for 95% confidence intervals (CIs) represent 95% CIs in pair-wise meta-analyses and 95% credible intervals (CrIs) in network meta-analysis. The result of a single study was provided as OR with 95% CI.
10 Any AE Rank 1 CZP Rank 2 IFX Rank 3 PLC Injection site reaction CZP IFX PLC Arthralgia SAEs Abdominal pain Headache 6 4 CZP IFX PLC CZP IFX PLC CZP IFX PLC CZP IFX PLC Nausea CZP IFX PLC Supplementary material Figure 4. Ranking of treatment strategies based on the probability of their protective effects on analyzed outcomes middle-term follow-up
11 Any AE 6 4 Rank 4 Rank 5 AEs leading to discontinuation of study drug Rank 4 ADA GLM IFX PLC Infections SAEs Rank 4 Rank 5 Injection site reaction 6 4 Rank 4 Rank 5 Serious infections Rank 4 Rank 5 Infections requiring antimicrobial treatment GLM IFX PLC Rank 4 ADA IFX PLC VDZ Supplementary material Figure 5. Ranking of treatment strategies based on the probability of their protective effects on analyzed outcomes long-term follow-up
12 Abdominal pain Rank 4 Rank 5 Headache 8 Arthralgia 6 4 Rank 4 Rank 5 Cough Rank 4 Rank 5 Pyrexia Nausea GLM PLC VDZ ADA PLC VDZ Pharyngitis GLM IFX PLC Upper respiratory tract infection 8 Rank 4 ADA IFX PLC VDZ Nasopharyngitis 6 4 Rank 4 Rank Rank 4 Rank 5 Supplementary material Figure 6. Ranking of treatment strategies based on the probability of their protective effects on analyzed outcomes (individual adverse events) long-term follow-up
Effectiveness and safety of vedolizumab for treatment of Crohn s disease: a systematic review and meta-analysis
Systematic review/meta-analysis Effectiveness and safety of vedolizumab for treatment of Crohn s disease: a systematic review and meta-analysis Paweł Moćko 1, Paweł Kawalec 1, Beata Smela-Lipińska 1, Andrzej
A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis
PharmacoEconomics (2018) 36:419 434 https://doi.org/10.1007/s40273-017-0601-6 SYSTEMATIC REVIEW A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis Ewa Stawowczyk 1 Paweł
New treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy
New treatment options in IBD: today and the future Silvio Danese Istituto Clinico Humanitas, Milan, Italy Date of preparation: October 2014 GLO/EYV/2014-00010h Overview of the late-stage IBD drug pipeline*
Outline. Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic. Biologic Drugs. Biologic Drugs. Biologic Drugs Anti-TNF
Outline Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic Types of biologic drugs How do they work? How effective are they? Safety/Toxicity concerns with biologics Biologic
Center for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review)
Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review) Behm BW, Bickston SJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
Cimzia shows duration of response up to week 26 in moderate to severe Crohn s patients who failed the intravenous infusion treatment infliximab.
C3073-0409 CIMZIA (certolizumab pegol) PROVIDES LONG-TERM REMISSION AND RESPONSE RATES IN INFLIXIMAB-REFRACTORY CROHN S PATIENTS Cimzia shows duration of response up to week 26 in moderate to severe Crohn
Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
DRAFT. Remission rates, calculated using observed case (OC) analyses were as follows: Year 1 Year 2 Year 3 Year 4 All patients 62.
DRAFT New Efficacy Data Shows Cimzia (certolizumab pegol) Provides Long-Term Remission of Moderate to Severe Crohn s Disease Regardless of Prior Anti-TNF Exposure, According to Data Presented at DDW Oral
Biologic Therapy for Ulcerative Colitis in 2015
5/6/215 Biologic Therapy for Ulcerative Colitis in 215 John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Bressler B, Marshall JK, et al. Gastroenterology 215;148: 135-58
Tumor Necrosis Factor-alpha 저해제가결핵발생에미치는영향
한국임상약학회지제 28 권제 4 호 Korean J Clin Pharm, Vol. 28, No. 4, 2018 Original Article Korean Journal of Clinical Pharmacy Official Journal of Korean College of Clinical Pharmacy pissn 1226-6051 eissn 2508-786X
1. Comparative effectiveness of vedolizumab
Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were
Positioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
Are Biologicals Safe Enough?
Are Biologicals Safe Enough? Dr Anne Duggan Director of Gastroenterology, John Hunter Hospital, Hunter New England Area Health Service (HNEAHS) Conjoint A/Professor, University of Newcastle, Australia
Moderately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
STELARA (ustekinumab) Clinical Study Report CNTO1275CRD3001
SYNOPSIS Name of Sponsor/Company Janssen Research & Development* Name of Investigational Product STELARA (ustekinumab) * Janssen Research & Development is a global organization that operates through different
Cimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
Carefirst.+.V Family of health care plans
Carefirst.+.V Family of health care plans CVS care mark POLICY Document for ENTYVIO The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific
Update on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
Cimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
Treatment Options. Suresh Pola, MD Kaiser San Diego
Treatment Options Suresh Pola, MD Kaiser San Diego Overview of Treatments! Medications! Diet! Complementary and Alternative Medicines! How to treat Pain Treatment Goals and Target! Goals of Treatment should
Cimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
Technology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta352
Vedolizumab for treating moderately to severely erely active Crohn's disease after prior therapy Technology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta352 NICE 2017. All rights
The Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
SYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
Severe IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
September 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
Gionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico
Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico Anti cell adhesion molecules Danese S, NEJM 2011 6 Steps leukocyte recruitment Fiorino G. et al. 2010 Vedolizumab Blocks Fewer Biological Pathways
Indirect costs of inflammatory bowel diseases: Crohn s disease and ulcerative colitis. A systematic review
Systematic review/meta-analysis Indirect costs of inflammatory bowel diseases: Crohn s disease and ulcerative colitis. A systematic review Paweł Kawalec Drug Management Department, Institute of Public
How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
2.0 Synopsis. Adalimumab M Clinical Study Report Final R&D/15/1054. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
2.0 Synopsis. Adalimumab M Clinical Study Report Final R&D/15/1093. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
Cimzia (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
Cimzia (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients Rapid, sustained and clinically meaningful improvement in wideranging patient-reported
Technology appraisal guidance Published: 25 February 2015 nice.org.uk/guidance/ta329
Infliximab, adalimumab and golimumab for treating moderately to severely erely active ulcerative colitis after the failure of conventional therapy Technology appraisal guidance Published: 25 February 2015
TNF-alpha inhibitors for ankylosing spondylitis(review)
Cochrane Database of Systematic Reviews Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MMS, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA MaxwellLJ,ZochlingJ,BoonenA,SinghJA,VerasMMS,TanjongGhogomuE,BenkhaltiJanduM,TugwellP,WellsGA.
Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
Case Example: Exposure Response to Support Extrapolation of Efficacy in Pediatric Ulcerative Colitis
Case Example: Exposure Response to Support Extrapolation of Efficacy in Pediatric Ulcerative Colitis Kerry Jo Lee, MD Medical Officer Division of Gastroenterology and Inborn Error Products Office of New
Ulcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13
Ulcerative Colitis Therapy Amy Morse November 30/13 GI for GP s Jasper AB Faculty Disclosure Faculty: Amy Morse Relationships with commercial interests: Grants/Research Support: Therapeutic Fellowship
2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
Opinion 24 July 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 HUMIRA 40 mg, solution for injection in pre-filled syringe B/2 x 0.8 ml pre-filled glass syringes with
Efficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
Emerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
PRIOR AUTHORIZATION REQUEST GUIDE
PRIOR AUTHORIZATION REQUEST GUIDE Drafting a Prior Authorization Request The following information is presented for informational purposes only and is not intended to provide reimbursement or legal advice.
Indications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
Pharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: Feb. 14, 2018 Last Revised: April 1, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
Drug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 3 Report March 2012 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of the is to summarize
New Cimzia data, with sites in the US, demonstrate safety and efficacy, increased participation in social activities for adult RA patients
Long-term Cimzia (certolizumab pegol) data demonstrated rapid sustained improvements in clinical outcomes and quality of life in moderate to severe rheumatoid arthritis (RA) patients New Cimzia data, with
Medical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
Infliximab may be considered medically necessary as first-line therapy (ie, initial treatment) for the following condition:
Medical Policy MP 5.01.15 Original Policy Date: February 2002 Last Review: 01/30/2018 Effective Date: 04/30/2018 Section: Prescription Related Policies 2.04.84 Measurement of Serum Antibodies to and Adalimumab
Pharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: June 9, 2019* Last Revised: Feb. 12, 2019 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
Carelirst.+.V Family of health care plans
Carelirst.+.V Family of health care plans CVS Caremark POLICY Document for ACTEMRA The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific
Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014
Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014 Ellen J. Scherl, MD, FACP, FACG, AGAF, FASGE, NYSGEF Director Jill Roberts Center for Inflammatory Bowel Disease Jill Roberts IBD Research
Humira. (adalimumab) Drug Update Slideshow NEW INDICATION
Humira (adalimumab) NEW INDICATION Drug Update Slideshow Introduction Brand name: Humira Generic name: Adalimumab Pharmacological class: Tumor necrosis factor (TNF) blocker Strength and Formulation: 10mg/0.2mL,
Regulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 10 Last Review Date: June 22, 2017 Humira Description Humira (adalimumab),
London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8
London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 1. Introduction Infliximab is a chimeric human-murine IgG1κ monoclonal antibody, which binds
Vedolizumab: policing leukocyte traffic
Oxford Inflammatory Bowel Disease MasterClass Vedolizumab: policing leukocyte traffic Dr Brian Feagan, London, Canada Vedolizumab : Policing Lymphocyte Traficking Brian G. Feagan Professor of Medicine,
Cost-Effectiveness Analysis of Crohn s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-a Antagonist
PharmacoEconomics (2018) 36:853 865 https://doi.org/10.1007/s40273-018-0653-2 ORIGINAL RESEARCH ARTICLE Cost-Effectiveness Analysis of Crohn s Disease Treatment with Vedolizumab and Ustekinumab After Failure
Pediatric Inflammatory Bowel Diseases
Pediatric Inflammatory Bowel Diseases Michael Stephens, M.D. Denny Sanford Pediatric Symposium November 21 2014, Sioux Falls, SD 2014 slide-1 Disclosures I have nothing to disclose 2014 slide-2 Objectives
Corporate Medical Policy
Corporate Medical Policy Measurement of Serum Antibodies to Infliximab, Adalimumab and File Name: Origination: Last CAP Review: Next CAP Review: Last Review: measurement_of_serum_antibodies_to_infliximab_and_adalimumab
Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of
Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
Emerging Therapies in IBD 2006
Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION VEDOLIZUMAB (Entyvio Takeda Canada Inc.) Indication: Ulcerative Colitis Recommendation: The CADTH Canadian Drug Expert Committee (CDEC) recommends
Treating inflammatory bowel disease
Treating inflammatory bowel disease Anti TNFa (Infliximab, Adalimumab and Golimumab) Information for patients Gastroenterology This leaflet should not replace the information provided by the drug manufacturer.
ENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
SCIENTIFIC DISCUSSION. London, 26 April 2007 Product name: Humira/Trudexa Procedure number: EMEA/H/C/ /II/33
SCIENTIFIC DISCUSSION London, 26 April 2007 Product name: Humira/Trudexa Procedure number: EMEA/H/C/481-482/II/33 1. Introduction Adalimumab is a recombinant human immunoglobulin (IgG 1 ) monoclonal antibody
Technology appraisal guidance Published: 26 January 2016 nice.org.uk/guidance/ta375
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed Technology
Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Remicade Page: 1 of 9 Last Review Date: June 22, 2017 Remicade Description Remicade (infliximab),
Drugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending
Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual
Selection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
Review Article A Meta-Analysis of Adalimumab for Fistula in Crohn s Disease
Hindawi Gastroenterology Research and Practice Volume 2017, Article ID 1745692, 8 pages https://doi.org/10.1155/2017/1745692 Review Article A Meta-Analysis of Adalimumab for Fistula in Crohn s Disease
o Your healthcare provider should test you for TB before starting CIMZIA.
Medication Guide CIMZIA (CIM-zee-uh) (certolizumab pegol) lyophilized powder or solution for subcutaneous use Read the Medication Guide that comes with CIMZIA before you start using it, and before each
62 HUMIRA (ADALIMUMAB) 62 Forecast assumptions 66 Humira forecast Bibliography 70 LIALDA (MESALAZINE MMX) 71 Lialda forecast
TABLE OF CONTENTS To request sample pages please contact us at getcloser@datamonitorhealthcare.com 8 EXECUTIVE SUMMARY 9 METHODOLOGY AND MARKET DEFINITION 9 Market definition for inflammatory bowel disease
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary
Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the
Adalimumab M Clinical Study Report Final R&D/17/0360
Methodology (Continued): Beginning at Week 8, subjects who developed a flare while receiving ew therapy or had a PCDAI 15 points higher than Baseline at any time during this study may have been discontinued
Criteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
Personalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
ENTYVIO (vedolizumab)
ENTYVIO (vedolizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
Study No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study
Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
Remicade and Friends What You Need to Know Treating the Patient on TNF-alpha Inhibitors and Related Meds
Remicade and Friends What You Need to Know Treating the Patient on TNF-alpha Inhibitors and Related Meds Scott Stienecker MD FACP FSHEA Medical Director for Epidemiology and Infection Prevention Parkview
CIMZIA (certolizumab pegol)
CIMZIA (certolizumab pegol) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
Practical Risk Management Tools for Patients with IBD. Garth Swanson MD Rush University Medical Center
Practical Risk Management Tools for Patients with IBD Garth Swanson MD Rush University Medical Center IBD Therapy Severity Tysabri Surgery Infliximab, i Adalimumab, Certilizumab Corticosteroids, Immunomodulators
COPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
ENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
Synopsis (C0168T37 ACT 1)
() Module 5.3 Protocol: CR004777 EudraCT No.: Not Applicable Title of the study: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients with
Public observer slides
Public observer slides Lead team presentation Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple
non commercial use only Supplementary 1 Search result
Supplementary 1 Search result Database, Platform and Coverage Search Date Number of references Retrieved Cochrane library via OvidSP January 2013 Cochrane Central Register of Controlled Trials January
Certolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
Northern Treatment Advisory Group. Biologic drugs for treatment-refractory moderately to severely active ulcerative colitis
Northern Treatment Advisory Group Biologic drugs for treatment-refractory moderately to severely active ulcerative colitis Lead author: Dominic McDermott Regional Drug & Therapeutics Centre (Newcastle)